Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00453128
Recruitment Status : Completed
First Posted : March 28, 2007
Last Update Posted : March 28, 2007
Information provided by:
Sociedade Galega de Reumatoloxía

Brief Summary:
The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.

Condition or disease

Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

Study Type : Observational
Enrollment : 240 participants
Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease
Study Start Date : January 1997
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

  • Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00453128

Meixoeiro Hospital
Vigo, Pontevedra, Spain, 36214
Sponsors and Collaborators
Sociedade Galega de Reumatoloxía
Principal Investigator: José M Pego-Reigosa, MD, PhD Meixoeiro Hospital, Vigo (Pontevedra) SPAIN Identifier: NCT00453128     History of Changes
Other Study ID Numbers: SGR1
First Posted: March 28, 2007    Key Record Dates
Last Update Posted: March 28, 2007
Last Verified: March 2007

Keywords provided by Sociedade Galega de Reumatoloxía:
Calcium Pyrophosphate
associated conditions

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Calcium, Dietary
Bone Density Conservation Agents
Physiological Effects of Drugs